PRESENTATION

Q1 2026 — Presentation

Q1 2026PDF · 31 pages2.4 MB
First-Quarter 2026
Sales and Earnings
Merck & Co., Inc., Rahway, N.J., USA
April 30, 2026

-- 1 of 31 --

Agenda
2
Strategy and Business Update
Robert M. Davis
Chairman and Chief Executive Officer
Agenda
Financial Results and Outlook
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Research Update
Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories
Question & Answer Session

-- 2 of 31 --

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and
expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to
pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If
underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future
events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements
can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

-- 3 of 31 --

Strategy and
Business Update
Robert M. Davis
Chairman and Chief Executive Officer
4

-- 4 of 31 --

¹Weber Shandwick/KCR Research, 2020 / AMO 2019 	5
$16.3B
Q1 Worldwide Sales
Strength in Oncology and Animal Health
Increasing contributions from new launches
+5% nominal
+3% ex-exchange
Achieved significant pipeline and regulatory progress:
• 	FDA accepted four filings across oncology portfolio including new
BLA for ifinatamab deruxtecan1 for priority review in SCLC
Oncology
• 	FDA approved once-daily IDVYNSO, a new, two-drug single-tablet
regimen of doravirine and islatravir for certain adults with
virologically suppressed HIV-1
Infectious Diseases
• 	Presented results from new studies evaluating enlicitide and
WINREVAIR at ACC 2026
Cardiometabolic & Respiratory
• 	Initiated pivotal Phase 2b/3 studies evaluating MK-8748, a TIE-
2/VEGF bispecific antibody, in NVAMD
Ophthalmology
• 	FDA approved NUMELVI, the first and only second-generation JAK
inhibitor for allergic dermatitis in dogs
Animal Health
1. In collaboration with Daiichi Sankyo

-- 5 of 31 --

66
Announced strategic acquisition 1 of Terns Pharmaceuticals
Adds TERN-701, an investigational next-generation, allosteric TKI
for treatment of certain patients with chronic myeloid leukemia
Science-driven business development that strengthens and
complements hematology pipeline
Potential best-in-class profile with opportunity to further improve
depth and duration of response in certain patients
Multibillion dollar commercial opportunity and growth driver in
the next decade, creating shareholder value
1. Transaction expected to close in May

-- 6 of 31 --

7
Executing Business Development
Actively pursuing additional science-driven,
value-creating transactions
Launching New Growth Drivers
Expect >20 new growth drivers, almost all of which have
blockbuster potential
Advancing Diverse & Expansive Pipeline
~80 Phase 3 studies ongoing
Transforming our
portfolio with next
wave of innovation
Significant commercial opportunity
Potential commercial opportunity of >$70B1 from new growth
drivers alone by the mid-2030s
1. Non-risk adjusted annual sales by the mid-2030s

-- 7 of 31 --

Financial Results
and Outlook
Caroline Litchfield
Executive Vice President and
Chief Financial Officer
8

-- 8 of 31 --

9
Q1 worldwide performance driven by demand for our innovative portfolio
Human Health
$14.3B+5% growth
+2% ex-exchange
$16.3B+5% nominal
+3% ex-exchange
WORLDWIDE SALES1 Animal Health
$1.8B+13% growth
+6% ex-exchange
1. Worldwide Sales includes Other Revenue

-- 9 of 31 --

Oncology: KEYTRUDA continues to benefit patients and drive growth
10
KEYTRUDA family1 sales of $8.0B increased
8%, driven by strong demand from metastatic
indications and robust uptake in earlier-stage
cancers
‒ 	Growth driven by usage in tumors
predominantly affecting women, including those
with certain breast and cervical cancers
‒ 	Increased use of KEYTRUDA in combination with
enfortumab vedotin in locally advanced or
metastatic urothelial cancer
‒ 	In the U.S., growth benefitted by ~$250M due
to timing of wholesaler purchases, as expected
‒ 	KEYTRUDA QLEX sales of $128M in 1Q26
following launch in 3Q25; permanent J-code
effective April 1st
1Q24 	1Q25 	1Q26
$6.9B
+24%2
$8.0B
+8%$7.2B
+6%
Growth rates exclude the impact of foreign exchange 1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX (available as KEYTRUDA SC in some markets) 2. ~4 percentage points of negative
impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market

-- 10 of 31 --

1Q24 	1Q25 	1Q26
Oncology: Continued impact for patients across broad portfolio
11
WELIREG sales grew 43%, driven by
continued launch uptake in international
markets and higher demand in the U.S.
Lynparza 1 alliance revenue grew 6%, primarily
due to higher demand in the U.S. and many
international markets
Lenvima 2 alliance revenue declined 2%
Growth rates exclude the impact of foreign exchange 1. In collaboration with AstraZeneca 2. In collaboration with Eisai
1Q24 	1Q25 	1Q26
$312M
+8%
$292M
+7% $341M
+6%
1Q24 	1Q25 	1Q26
$258M
+2%
$255M
+10%
$256M
-2%
$85M
+102% $137M
+63%
$199M
+43%

-- 11 of 31 --

Vaccines & Infectious Diseases: Protecting lives globally
1Q24 	1Q25 	1Q26
1Q24 	1Q25 	1Q26
$1.1B
-22%
Growth rates exclude the impact of foreign exchange 1. Launched in 3Q24
GARDASIL sales of $1.1B decreased 22%,
driven by lower demand in China and Japan,
consistent with expectations
‒ 	In the U.S., sales declined 10% primarily due to
the timing of CDC purchases, partially offset by
price
CAPVAXIVE 1 sales of $142M increased 31%
driven by uptake from ongoing launches in
certain international markets
‒ 	In the U.S., growth was driven by increased
demand from both retail pharmacies and non-
retail customers, partially offset by a reduction
in wholesaler inventory
$142M
+31%
$2.2B
+17%
$1.3B
-40%
$107M

-- 12 of 31 --

Cardiometabolic & Respiratory: Continuing to drive impact for patients
with successful ongoing launches
WINREVAIR1 sales of $525M driven by
continued growth in new patient starts and
total prescriptions
‒ 	In the U.S., >1,600 new patients prescribed and
>29,500 total prescriptions dispensed
‒ 	Ex-U.S., making progress with approvals and
reimbursement
OHTUVAYRE 2 sales of $131M reflect strong
growth in total prescriptions
‒ 	Sequential sales decline due to Medicare
deductible resets and CMS reimbursement
change
1Q24 	1Q25 	1Q26
$1.7B
+40%
1Q24 	1Q25 	1Q26
$131M
Growth rates exclude the impact of foreign exchange 1. Launched in 2Q24 2. 1Q26 sales following the closing of the acquisition of Verona Pharma on October 7th , 2025 3. Sales reported by Verona Pharma
$280M
$525M
+87%
$71M3

-- 13 of 31 --

Animal Health: Strong growth driven by livestock and companion animal
14
Animal Health sales increased 6% to $1.8B
‒ 	Livestock sales grew 8%, driven by higher
demand for ruminant and poultry products as
well as price
‒ 	Companion Animal sales grew 4% driven by new
product launches and price, partially offset by
lower demand for other products in portfolio due
to lower vet visits
1Q24 	1Q25 	1Q26
$1.5B
+4% 1
$1.6B
+10%
$1.8B
+6%
Growth rates exclude the impact of foreign exchange 1. ~3 percentage points of negative impact of foreign exchange due to devaluation of Argentine peso, which was largely offset by inflation-related price
increases, consistent with practice in that market

-- 14 of 31 --

Q1 2026 non-GAAP financial results summary 1
$ in billions, except LPS / EPS amounts
15
1. The company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee
compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or
superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q1 2026 non-GAAP results include a charge of
$9.0 billion related to the acquisition of Cidara Therapeutics 3. Q1 2026 non-GAAP results include a charge of $3.62 per share related to the acquisition of Cidara Therapeutics. 4. Q1 2026 GAAP LPS of
$(1.72).
Q1 2026 	Q1 2025 	Change Change
Ex-FX
Sales 	$16.3 	$15.5 	+5% 	+3%
Non-GAAP Gross Margin 	81.9% 	82.2% 	-0.3 pts 	+0.1 pts
Non-GAAP Operating
Expenses2 	$15.2 	$6.1 	N/M 	N/M
Non-GAAP Tax Rate 	-43.5% 	14.2% 	N/M 	N/A
Non-GAAP (Loss) /
Earnings Per Share3,4 	$(1.28) 	$2.22 	N/M 	N/M

-- 15 of 31 --

16
Updated 2026 financial outlook
1. Guidance does not assume any additional significant potential business development transactions 2. Outlook does not reflect expected ~$5.8B, or ~$2.35 per share, one-time charge for the proposed
acquisition of Terns Pharmaceuticals
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue 	$65.5B to $67.0B 	$65.8B to $67.0B • 	Assumes ~1 percentage point positive impact from FX
• 	Implies +1% to +3% nominal (+0% to +2% ex-FX)
Non-GAAP
Gross Margin Rate ~82.0% 	~82.0%
Non-GAAP
Operating Expenses1, 2 	$35.9B to $36.9B 	$36.0B to $36.8B 	• 	Includes $9B charge related to acquisition of Cidara
Other (Income) / Expense 	~$1.3B of expense 	~$1.3B of expense • 	Includes financing costs related to acquisitions of Verona
and Cidara
Tax Rate 	~23.5% to 24.5% 	~23.5% to 24.5% 	• 	Includes impact of non-tax deductible charge for Cidara
Shares Outstanding 	~2.48B 	~2.48B 	• 	Assumes ~3B of share repurchases
Non-GAAP EPS1,2 	$5.00 to $5.15 	$5.04 to $5.16 • 	Includes ~$3.62 negative impact related to upfront
charge for acquisition of Cidara
• 	Assumes ~$0.10 positive impact from FX

-- 16 of 31 --

Key modeling considerations
17
• 	Anticipate minimal sales in 2Q
given expected seasonality and
continued high levels of RSV
mAb inventory in marketplace
ENFLONSIA	KEYTRUDA
• 	In the U.S., expect headwind
from timing of wholesaler
purchases in 3Q
SG&A
• 	Expect expenses to increase
over remainder of year due to
investment in launches

-- 17 of 31 --

Remain committed to balanced capital allocation strategy
Q1 Spend ($ in billions) 1
18
Augmented our pipeline and
portfolio with value-
enhancing business
development while investing
in our pipeline and business
as well as returning cash to
shareholders
1. Reflects quarter spend 2. Reflects R&D excluding Business Development
Capital allocation order of priority
2
$3.1
$1.0 $2.1
$9.1
$0.9
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase

-- 18 of 31 --

Research Update
Dr. Dean Y. Li
Executive Vice President and President,
Research Laboratories
19

-- 19 of 31 --

Important updates across cardiometabolic and respiratory portfolio
20
Enlicitide
• 	Phase 3 results support ambition to
bring first approved oral PCSK9i
designed to have antibody-like
LDL-C lowering to a broad
population globally
• 	Percent LDL-C reduction from
baseline as demonstrated:
WINREVAIR
• 	Totality of evidence from Phase 2
CADENCE study provides strong
rationale for Phase 3 development
in CpcPH-HFpEF
• 	Robust primary endpoint4 results
at 0.3mg/kg dose:
• 	Additional findings from
exploratory secondary endpoints at
0.3mg/kg dose include:
2026 AHA/ACC Multisociety
Guidelines3
• 	Updated guidelines support early
and aggressive treatment to
reduce lifetime cumulative LDL-C
exposure and restore concrete
targets
• 	Key goals include:
– 	<55 mg/dL for very high risk ASCVD
– 	<70 mg/dL for high risk ASCVD and
primary prevention patients with
PREVENT score >10
• 	Most patients with ASCVD will
qualify for an LDL-C goal of <55
mg/dL
-57.11
-59.62
-58.2
-64.6
1. Per statistical analysis plan 2. Reanalysis (post-hoc) conducted to remove imputed biologically impossible baseline values 3. Blumentahl, et al., (2026) Circulation, 153. Published online March 13, 2026.
4. The primary endpoint was also statistically significant at the 0.7 mg/kg dose 5. The secondary endpoint of 6MWD did not reach statistical significance at the 0.7mg/kg dose, and subsequent secondary
endpoints were not eligible to be tested due to the prespecified hierarchical testing strategy
6MWD5 	+20.3 meters
TTCW5 	Prolonged TTCW (HR: 0.18)
PVR 	-1.02 Wood units

-- 20 of 31 --

Continuing to advance cancer care with broad portfolio and pipeline
21
KEYTRUDA
• 	KEYNOTE-B96: FDA and EC
approved KEYTRUDA in
combination with paclitaxel, with or
without bevacizumab, for
treatment of PD-L1+ cisplatin-
resistant ovarian cancer
• 	KEYNOTE-B151: Findings showed
perioperative KEYTRUDA in
combination with enfortumab
vedotin reduced risk of EFS events
by 47% and risk of death by 35% vs
neoadjuvant chemotherapy2 for
treatment of cisplatin-eligible
MIBC
‒ 	Sixth study of KEYTRUDA-based
regimen to demonstrate OS in earlier
stage cancer
− 	PDUFA date August 17, 2026
I-DXd4
• 	Announced priority review for BLA
filing based on Phase 2 IDeate-
Lung01 and Phase 1/2 IDeate-Pan
Tumor01 trials for extensive-stage
SCLC with disease progression on
or after platinum-based
chemotherapy
− 	PDUFA date October 10, 2026
WELIREG
• 	LITESPARK-022: WELIREG plus
KEYTRUDA demonstrated a 28%
reduction in the risk of disease
recurrence or death compared to
KEYTRUDA alone in adjuvant RCC
setting
− 	PDUFA date June 19, 2026
• 	LITESPARK-011: WELIREG plus
Lenvima3 demonstrated a 30%
reduction in the risk of disease
progression or death versus
cabozantinib in previously treated
advanced RCC with disease
progression on or after anti PD-
1/PD-L1 therapy
− 	PDUFA date October 4, 2026
1. In collaboration with Pfizer and Astellas 2. Regimen versus neoadjuvant chemotherapy (gemcitabine plus cisplatin) and surgery 3. In collaboration with Eisai 4. In collaboration with Daiichi Sankyo

-- 21 of 31 --

Terns Pharmaceuticals acquisition 1 expands hematology pipeline
22
Chronic myeloid leukemia
• 	Bone marrow cancer driven by BCR::ABL fusion
gene
• 	Advances in treatment have transformed CML to
chronic disease that can require life-long
treatment
• 	Significant unmet need remains for improved
efficacy, safety and convenience
• 	Quality of life and long-term tolerability
increasingly important goals as treatment
duration extends
TERN-701
• 	Potent, oral, next-generation allosteric BCR::ABL
TKI
• 	Highly selective, with a novel binding site
• 	Potential best-in-class efficacy
1. Transaction expected to close in May

-- 22 of 31 --

Building on our strong legacy in combatting infectious diseases
23
HIV
• 	FDA and MHLW approved IDVYNSO
for treatment of HIV-1 infection in
adults who are virologically
suppressed
• 	First two-drug regimen without an
HIV integrase strand transfer
inhibitor to demonstrate non-
inferior efficacy and a generally
comparable safety profile versus
bictegravir / emtricitabine / tenofovir
alafenamide
RSV
• 	Presented positive top line results for
ENFLONSIA for prevention of RSV disease in
infants and children under two years of age at
increased risk over two seasons based on Phase 3
SMART study at RSV-VW-26
• 	EC approved for newborns and infants during
their first season
• 	Important new treatment option as health needs
of adults living with HIV change over time

-- 23 of 31 --

Progressing late-stage ophthalmology pipeline
24
MK-8748
• 	Potential first-in-class bispecific inhibiting VEGF
and directly activating Tie2 pathway
• 	Initial Phase 1/2a RIOJA data demonstrated MK-
8748 was well tolerated with no drug-related AEs
or SAEs and rapid, sustained structural and
functional responses
• 	Initiated two Phase 2b/3 studies, MALBEC and
TORRONTES, for treatment of NVAMD
Mechanism of action
• 	Antibody binds Tie2 and VEGF aiming to stabilize
blood retinal barrier and reduce free VEGF

-- 24 of 31 --

Significant late-stage pipeline milestones over next six months
25
1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX 2. In collaboration with Pfizer and Astellas 3. In collaboration with Daiichi Sankyo 4. In collaboration with Gilead
Oncology
ASCO Investor Event
• 	Monday, June 1st
KEYTRUDA Family 1
• 	KEYNOTE-B152 PDUFA date August 17 th
WELIREG
• 	LITESPARK-022 PDUFA date June 19th
• 	LITESPARK-011 PDUFA date October 4th
I-DXd 3
• 	IDeate-Lung013 PDUFA date October 10 th
Cardiometabolic & respiratory
WINREVAIR
• 	HYPERION PDUFA date September 21st
Enlicitide
• 	CNPV process progressing
HIV
Islatravir/Lenacapavir4
• 	Readout of Phase 3 ISLEND-1 and ISLEND-2 trials for
HIV treatment
Immunology
Tulisokibart
• 	PCD in August for Phase 3 ATLAS trial in UC
• 	PCD in May for Phase 2 ATHENA trial in SSc-ILD
Ophthalmology
MK-3000
• 	PCD in September for Phase 3 BRUNELLO trial in DME
MK-8748
• 	Readout of Phase 2a RIOJA trial in NVAMD, DME, and
RVO

-- 25 of 31 --

Q&A
Robert M. Davis
Chairman and Chief Executive Officer
Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Peter Dannenbaum
Senior Vice President, Investor Relations

-- 26 of 31 --

27
Appendix

-- 27 of 31 --

Q1 2026 GAAP financial results summary
$ in billions, except LPS / EPS amounts
28
Q1 2026 	Q1 2025 	Change 	Change Ex-FX
Sales 	$16.3 	$15.5 	+5% 	+3%
Operating Expenses
(SG&A and R&D)1 $15.3 	$6.2 	N/M 	N/M
Tax Rate 	-20.1% 	13.9% 	N/M 	N/A
GAAP (Loss) / Earnings
per Share2 $(1.72) 	$2.01 	N/M 	N/M
1. Q1 2026 GAAP results include a charge of $9.0 billion related to the acquisition of Cidara Therapeutics 2. Q1 2026 GAAP results include a charge of $3.62 per share related to the acquisition of Cidara
Therapeutics

-- 28 of 31 --

$12.7
$3.8
$8.2
$20.5
$4.8
$0
$3
$6
$9
$12
$15
$18
$21
$24
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
Capital allocation: Trailing twelve months
29
Capital allocation order of priority
2
1
Executing upon balanced capital allocation strategy
1. Reflects R&D excluding Business Development 2. Includes BD payments reflected in operating cash flow
Over the past 12 months
Committed to the dividend
2017 	2018 	2019 	2020 	2021 	2022 	2023 	2024 	2025 	2026E
Dollars per Share
+2% 	+2%
+15% +11% +7% +6% +6%
+5%
+5%
+5%Capital investments
2025 to 2029
~$20B
Over 5 years, including more than $12B in the U.S.
Well-positioned balance sheet with
capacity to fund additional value-
enhancing business development
opportunities

-- 29 of 31 --

Broad and innovative pipeline to address significant unmet medical needs
30
As of April 30, 2026
Phase 3
Oncology
MK-1022 (patritumab
deruxtecan) 1
Breast
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-1084 (calderasib) 1
CRC
NSCLC
MK-2140 (zilovertamab
vedotin)
Hematological Malignancies
MK-2400 (ifinatamab
deruxtecan) 1
Esophageal
Prostate
SCLC (EU)
MK-2870 (sacituzumab
tirumotecan) 1
Bladder
Breast
Cervical
Endometrial
Gastric
NSCLC
Ovarian
MK-1406
Influenza
LAGEVRIO (MK-4482) 1,3
COVID-19 (U.S.)
MK-8527
HIV-1 PrEP
MK-8591A (doravirine +
islatravir)
HIV-1 Infection (EU)
MK-8591D (islatravir +
lenacapavir) 1,2
HIV-1 Infection
KEYTRUDA (MK-3475)
SCLC
MK-3543 (bomedemstat)
Myeloproliferative Disorders
MK-5684 (opevesostat)
Prostate
MK-5909 (raludotatug
deruxtecan) 1
Ovarian
LYNPARZA (MK-7339) 1
NSCLC
SCLC
V940 (intismeran autogene) 1
Melanoma
NSCLC
Infectious Diseases
MK-1022 (patritumab
deruxtecan) 1
Biliary
Bladder
Cervical
Endometrial
Esophageal
Gastric
HCC
Melanoma
NSCLC
Ovarian
Pancreatic
Prostate
MK-1084 (calderasib) 1
Solid Tumors
MK-2400 (ifinatamab
deruxtecan) 1
Biliary
Bladder
Breast
Cervical
Endometrial
HCC
HNSCC
Melanoma
NSCLC
Ovarian
Pancreatic
Solid Tumors
MK-2870 (sacituzumab
tirumotecan) 1
Biliary
Esophageal
Neoplasm Malignant
Pancreatic
Oncology
Infectious Diseases
MK-8591B (islatravir +
ulonivirine)
HIV-1 Infection
MK-5475
PH-COPD
MK-5884A (ensifentrine +
glycopyrrolate)
COPD
MK-6024 (efinopegdutide)
MASH
MK-7262
Atherosclerosis
WINREVAIR (MK-7962)
Pulmonary Hypertension due
to Left Heart Disease
Cardiometabolic &
Respiratory
MK-7240 (tulisokibart)
Axial Spondyloarthritis
Hidradenitis Suppurativa
Psoriatic Arthritis
Rheumatoid Arthritis
Systemic Sclerosis
MK-8690
Ulcerative Colitis
Immunology
MK-3120
Bladder
KEYTRUDA (MK-3475)
Prostate
KEYTRUDA QLEX (MK-3475A)
Hematological Malignancies
(U.S.)
MK-5684 (opevesostat)
Breast
Endometrial
Ovarian
MK-5909 (raludotatug
deruxtecan) 1
Cervical
Endometrial
Gastric
NSCLC
RCC
SCLC
MK-6070 (gocatamig) 1
SCLC
WELIREG (MK-6482)
Breast
V940 (intismeran autogene) 1
Bladder
RCC
MK-1167
Alzheimer’s Disease
MK-2214
Alzheimer’s Disease
Neuroscience
Under regulatory review
Oncology
MK-2400 (ifinatamab deruxtecan)1
SCLC (U.S.)
KEYTRUDA (MK-3475)
Breast (U.S.)
Cisplatin Eligible MIBC (U.S.)
Cisplatin Ineligible MIBC (EU, JPN)
Ovarian (JPN)
KEYTRUDA QLEX (MK-3475A)
Breast (U.S.)
Cisplatin Eligible MIBC (U.S.)
WELIREG (MK-6482)
Clear Cell RCC Following Nephrectomy (U.S.) 5
Previously Treated Advanced RCC (U.S., JPN) 1
MK-7240 (tulisokibart)
Crohn’s Disease
Ulcerative Colitis
Immunology
Cardiometabolic &
Respiratory
MK-0616 (enlicitide decanoate)
Hypercholesterolemia (U.S.)
MK-30004
Diabetic Macular Edema
MK-8748 4
Neovascular Age-Related
Macular Degeneration
Ophthalmology
V181
Dengue Fever Virus
Vaccines
Phase 3	Phase 2
Infectious Diseases
ENFLONSIA (MK-1654)
Respiratory Syncytial Virus (JPN)
Cardiometabolic &
Respiratory
MK-0616 (enlicitide decanoate)
Primary Hypercholesterolaemia or Mixed
Dyslipidaemia (EU)
WINREVAIR (MK-7962)
Pulmonary arterial hypertension (U.S.)
1. Being developed in a collaboration 2. On partial clinical hold for higher doses of islatravir than those used in current clinical trials 3. Available in the U.S. under Emergency Use Authorization 4. Program is in
Phase 2/3 studies 5. Under review for combination use with KEYTRUDA or KEYTRUDA QLEX

-- 30 of 31 --

31
6MWD = 6-minute walk distance
AE = Adverse event
AHA/ACC = American Heart Association/American College of Cardiology
ASCVD = Atherosclerotic cardiovascular disease
BCR::ABL = Breakpoint Cluster Region – Abelson murine leukemia viral
oncogene homolog
BLA = Biologics license application
CML = Chronic myeloid leukemia
CNPV = Commissioner's National Priority Voucher
CpcPH-HFpEF = Combined post- and pre-capillary pulmonary hypertension
in heart failure with preserved ejection fraction
DME = Diabetic macular edema
EFS = Event free survival
HeFH = Heterozygous familial hypercholesterolemia
HIV-1 = Human Immunodeficiency Virus Type 1
I-DXd = Ifinatamab deruxtecan
JAK = Janus kinase
LDL-C = Low-density lipoprotein cholesterol
MAb = Monoclonal antibody
Acronyms
MIBC = Muscle invasive bladder cancer
NVAMD = Neovascular age-related macular degeneration
OS = Overall survival
PCD = Primary completion date
PCSK9i = Proprotein convertase subtilisin/kexin type 9 inhibitor
PD-1/PD-L1 = Programmed cell death protein-1/Programmed cell death
ligand-1
PVR = Pulmonary vascular resistance
RCC = Renal cell carcinoma
RSV = Respiratory syncytial virus
RVO = Retinal vein occlusion
SAE = Serious adverse event
SCLC = Small cell lung cancer
SSc-ILD = Systemic sclerosis associated interstitial lung disease
TIE-2 = Tyrosine kinase with immunoglobulin-like and EGF-like domains 2
TKI = Tyrosine kinase inhibitor
TTCW = Time to clinical worsening
UC = Ulcerative colitis
VEGF = Vascular endothelial growth factor

-- 31 of 31 --